West (WST) Q3 Earnings Power Margin Expansion And GLP1 Growth

West Pharmaceutical Services stock slipped about 1.1% on Friday to around US$412, a modest giveback after a strong run into this earnings print. The Q3 2026 release, though, landed with real force. Revenue reached US$874.5m and basic earnings per share came in at US$3.04, both pointing to a quarter powered by higher value drug packaging and devices rather than one-off noise.

Short term traders saw a small red day. Long term holders saw another data point in a margin story that now stretches across multiple quarters and feeds directly into how this premium multiple is judged.

Love West Pharmaceutical Services’ premium margins but want a wider set of high quality balance sheet stories to compare it against? Line this quarter up against our list of solid balance sheet and fundamentals stocks (25 results).

Q3 2026 Earnings Summary

• Revenue (Q3 2026 vs. Q3 2025): US$874.5m vs. US$804.6m (top line higher year over year)
• Net Income (Excl. Extra Items, Q3 2026 vs. Q3 2025): US$214.0m vs. US$140.0m (profit level higher year over year)
• Basic EPS (Q3 2026 vs. Q3 2025): US$3.04 vs. US$1.94 (earnings per share higher year over year)
• Gross Margin (Q3 2026 vs. Q3 2025): 39.7% vs. 36.6% (profitability per dollar of sales improved year over year)

Earnings tell you how strong West Pharmaceutical Services looked in the quarter, but the durability of those results lives in the cash flows behind them. That is what valuation focused investors tend to watch most closely.

On West Pharmaceutical Services' own cash generation profile, and treating the discounted cash flow output as a hypothetical yardstick rather than a verdict, the stock could be a striking 30% overvalued.

West Pharmaceutical: HVP And GLP-1 Story Tested

West Pharmaceutical Services is often framed as a high value components and GLP-1 execution story. That ambition shows up clearly here:

"The continued growth in GLP-1s, which made up about 10% of West Pharmaceutical Services revenues in the second quarter and are expected by management to grow at a high teens rate for the full year, together with participation in generic GLP-1 launches in multiple countries, could support revenue growth and earnings as higher value elastomer components are supplied into a broader therapy base."

GLP-1 related revenues reached about 12% of sales in Q3 and HVP components delivered roughly 20% organic growth, helping organic revenue reach 11.9% and supporting the raised full year revenue and EPS guidance.

West Pharmaceutical: Vantage Transition Risk Under The Microscope

Concerns focus on whether the shift in West Vantage and drug handling ramps can unsettle profit quality at West Pharmaceutical Services.

"The transition in contract manufacturing due to exiting CGM contracts and filling those with GLP-1 and drug handling may create variability and pressure on segment margins and revenue consistency. This is particularly relevant because West Vantage is expected to see a trough in Q3 2026, while the Dublin drug handling program only gradually ramps toward a targeted more than US$60 million of revenue and gross margins above 30%."

West Vantage revenue declined organically by about 6.6% and management described a trough in Q3, yet group gross margin reached 39.7% and operating margin expanded, which limited the impact of that softness at the consolidated level.

The price and this Narrative do not agree. → Uncover what this Narrative says West Pharmaceutical Services is actually worth.

Hunt For Mispriced Compounding Power

West Pharmaceutical Services just gave investors a detailed update on how its high value components business is progressing. The real opportunity could be identifying stocks that might be undervalued before the market potentially narrows that gap.

• Company 1 - 31% below our estimate - builds massive AI superclusters used as a core multi-cloud backbone for leading model deployment.
• Company 2 - 30% below our estimate - ties AI copilots, developer tools and security into a single subscription stack for enterprise workflows.
• Company 3 - 27% below our estimate - supplies grid diagnostics and test systems that support electrification, reliability programs and infrastructure replacement.

Three companies from the same screener. Open every one of the 30 undervalued companies on it →

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com